Ischemic Heart Disease
Conditions
Keywords
coronary stent, ischemic heart disease, acute coronary syndrome
Brief summary
This study aims to evaluate the efficacy and safety of abluminal biodegradable polymer ultrathin sirolimus-eluting stent (Genoss stent) as compared with a durable-polymer everolimus-eluting stent (Xience stent) in patients with coronary artery disease.
Detailed description
After the introduction of the drug-eluting stents (DES), the rates of device-related failure or target lesion failure (TLF) such as restenosis has been markedly decreased, compared with the era of bare-metal stents. Nevertheless, the risk of ischemic events including very late stent thrombosis after percutaneous coronary intervention (PCI) has still remained even though the use of DES, presumably because of hypersensitivity to the polymer with persistent inflammation and delayed re-endothelialization. To overcome these issues, second-generation DES with thinner stent strut and biocompatible or biodegradable polymer were developed. Several trials demonstrated that second-generation DES provides more favorable outcome in comparison with first-generation DES. Especially, among second-generation DES, biodegradable polymer DES showed better ischemic outcomes compared to durable polymer DES in some studies. Genoss DES™ (Genoss Company Limited, Suwon, Korea) is one of newer second-generation DESs with a cobalt-chromium platform with an abluminal biodegradable polymer containing sirolimus. The Genoss DES™ is the first Korean sirolimus-eluting stent on the market and it has ultrathin strut with 70 μm strut thickness with 3 μm thin abluminal polymer coating containing Sirolimus. The polymer is designed to release approximately 70% of the total drug amount within 30 days of the implantation and is entirely absorbable within 9 months. Thus, only the metal component of the stent will remain. In the first-in-man trial comparing Genoss DES™ and Promus Element™ stent (Boston Scientific Co., Natick, MA, USA), angiographic and clinical outcomes were similar at a 9-month follow-up. However, the study was too small to conclude that the Genoss DES™ is safe and efficient for de novo coronary stenosis. To date, there has been no large-scale randomized trial evaluating the safety and efficacy of Genoss DES™. Therefore, the purpose of this trial is to determine the efficacy and safety of Genoss DES™ as compared with Xience everolimus-eluting stent (Abbott Vascular, Santa Clara, California, USA) which is widely used and has proven efficacy and safety.
Interventions
DEVICEImplanatation of Genoss DES sirolimus-eluting coronary system
Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Genoss stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
DEVICEImplanatation of Xience DES everolimus-eluting coronary system
Percutaneous coronary intervention will proceed as per clinical guidelines, under operator's discretion. Xience stent will be implanted if the lesion is deemed necessary to be revascularized by stenting
Sponsors
Genoss Company Limited, Suwon, Korea
Samsung Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
① Subject must be at least 19 years of age ② Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily. ③ Patients with stable coronary artery disease or acute coronary syndrome and at least one lesion with greater than 50% diameter stenosis suitable for stent implantation
Exclusion criteria
* Pregnant women ② Patients unable to provide consent, ③ Patients with known intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, heparin or components of drug-eluting stents (sirolimus or everolimus) * Patients who have non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| TLF at 1 year | 1 year | A composite of cardiac death, target vessel-MI, or clinically indicated TLR by percutaneous or surgical methods at 1 year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Target vessel failure | 1 and 3 years | a composite of cardiac death, target vessel-MI, or clinically indicated target-vessel revascularization \[TVR\] by percutaneous or surgical methods at 1 and 3 years |
| All-cause death | 1 and 3 years | All-cause death at 1 and 3 years |
| Cardiac death | 1 and 3 years | Cardiac death at 1 and 3 years |
| MI | 1 and 3 years | Myocardial infarction, as defined by the protocol of this study, at 1 and 3 years |
| Stent thrombosis | 1 and 3 years | F. Stent thrombosis (definite or probable by Academic Research Consortium \[ARC\] definition) at 1 and 3 years |
| All-cause death or MI | 1 and 3 years | All-cause death or MI at 1 and 3 years |
| Cardiac death or MI | 1 and 3 years | Cardiac death or MI at 1 and 3 years |
| TLF at 3 years | 3 years | A composite of cardiac death, target vessel-MI, or clinically indicated TLR by percutaneous or surgical methods at 3 year |
| Stroke | 1 and 3 years | Stroke at 1 and 3 years |
| Clinically indicated TLR | 1 and 3 years | Clinically indicated target lesion revascularization at 1 and 3 years |
| Clinically indicated TVR | 1 and 3 years | Clinically indicated target vessel revascularization at 1 and 3 years |
| Any revascularization | 1 and 3 years | Any revascularization at 1 and 3 years |
| Major bleeding | 1 and 3 years | Major Bleeding (BARC \[Bleeding Academic Research Consortium\] types 3 or 5) at 1 and 3 years |
| Bleeding | 1 and 3 years | Bleeding (BARC type 2, 3, or 5) at 1 and 3 years |
| Restricted mean survival time for the TLF | 1 and 3 years | Restricted mean survival time for the TLF over 1 and 3 years |
| Cardiac death, MI or stent thrombosis | 1 and 3 years | Cardiac death, MI or stent thrombosis at 1 and 3 years |
Countries
South Korea
Contacts
Primary ContactHyeon-Cheol Gwon, MD, PhD
Outcome results
None listed